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Abstract
Background: Nicotinic acetylcholine (Ach) receptors are ligand-gated pentameric ion channels whose main
function is to transmit signals for the neurotransmitter Ach in peripheral and central nervous system. However,
the α7 nicotinic receptor has been recently found in several non-neuronal cells and described as an important
regulator of cellular function. Nicotine and ACh have been recently reported to inhibit tumor necrosis factor-α
(TNF-α) production in human macrophages as well as in mouse microglial cultures. In the present study, we
investigated whether the stimulation of α7 nicotinic receptor by the specific agonist nicotine could affect the
functional state of activated microglia by promoting and/or inhibiting the release of other important pro-
inflammatory and lipid mediator such as prostaglandin E2.
Methods:  Expression of α7 nicotinic receptor in rat microglial cell was examined by RT-PCR,
immunofluorescence staining and Western blot. The functional effects of α7 receptor activation were analyzed
in resting or lipopolysaccharide (LPS) stimulated microglial cells pre-treated with nicotine. Culture media were
assayed for the levels of tumor necrosis factor, interleukin-1β, nitric oxide, interleukin-10 and prostaglandin E2.
Total RNA was assayed by RT-PCR for the expression of COX-2 mRNA.
Results: Rat microglial cells express α7 nicotinic receptor, and its activation by nicotine dose-dependently
reduces the LPS-induced release of TNF-α, but has little or no effect on nitric oxide, interleukin-10 and
interleukin-1β. By contrast, nicotine enhances the expression of cyclooxygenase-2 and the synthesis of one of its
major products, prostaglandin E2.
Conclusions:  Since prostaglandin E2 modulates several macrophage and lymphocyte functions, which are
instrumental for inflammatory resolution, our study further supports the existence of a brain cholinergic anti-
inflammatory pathway mediated by α7 nicotinic receptor that could be potentially exploited for novel treatments
of several neuropathologies in which local inflammation, sustained by activated microglia, plays a crucial role.
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Background
The inflammatory response is in the first instance a mech-
anism of self-defense, set by the innate immune system
against endogenous and exogenous insults, and essential
for the survival of the organism. Inflammation must be
tightly regulated as deficiency as well as excess in its
response will result in pathological conditions, such as
immunodeficiency or chronic inflammatory diseases [1].
In the last decade increasing evidence has highlighted the
role of inflammation in most brain pathologies, including
immune-mediated diseases such as multiple sclerosis,
acute neurodegeneration following ischemia or trauma,
and, more recently, chronic neurodegenerative diseases
[2].
Among the endogenous mechanisms that regulate the
inflammatory response, cross-talk between the immune
and nervous systems play an important role. In particular,
it has been shown that electric stimulation of the vagus
nerve attenuates the inflammation during endotoxemia in
rats [3], and that acetylcholine (ACh), the main parasym-
pathetic neurotransmitter, effectively deactivates periph-
eral macrophages and inhibits the release of pro-
inflammatory mediators, including the cytokine tumor
necrosis factor-α (TNF-α). The ACh-dependent macro-
phage deactivation is mediated by the α7 subunit of the
nicotinic ACh receptor (herein referred as α7 subunit),
which is expressed in peripheral macrophages and has
been described as essential for the so called "cholinergic
anti-inflammatory pathway" [4,5].
Neuronal acetylcholine receptors (nAChRs) are ligand-
gated ion channels, which belong to a large family of neu-
rotransmitter receptors that includes the GABAA, glycine
and 5-HT3 receptors [6]. Each nAChR consists of five
homologous or identical subunits arranged around a cen-
tral ion channel whose opening is controlled by ACh, nic-
otine and other receptor agonists [6]. At least 8 α subunits
(α2–9) and three β subunits (β2–4) have been identified
and the combinatorial association of different α and β
subunits results in a variety of nAChRs [7].
In addition to neurons and peripheral macrophages, sev-
eral studies have demonstrated the expression of nAChRs
in cell types both within and outside the nervous system
[8]. In the CNS, the presence of nAChRs has been demon-
strated in O2A-oligodendrocyte precursor cells but not in
adult differentiated oligodendrocytes, suggesting that
receptor expression is developmentally regulated [9]. Cul-
tured hippocampal astrocytes express functional α7 recep-
tors [10] and cortical astrocytes express both nicotinic and
muscarinic receptors [11]. A functional α7 nicotinic
receptor has been recently described in murine microglial
cells [12]. In peripheral organs, human and rat epithelial
and endothelial cells express functional α7 receptors, as
well as other nicotinic subunits such as α3, α5, β2 and β4
[13,14]. Acute or chronic exposure to nicotine has been
shown to influence cell viability and motility of bronchial
epithelial and endothelial cells [13]. Furthermore, nico-
tine has been shown to suppress the antimicrobial activi-
ties of murine alveolar macrophages [15]. Lymphocytes
present both muscarinic and nicotinic receptors and it has
been demonstrated that the interaction with antigen pre-
senting cells enhances the synthesis and release of ACh
[16]. These observations suggest that ACh might function
as an important modulator of cellular interactions and
immune functions.
Epidemiological studies indicate that nicotine, besides its
immunosuppressive effects, may be protective against the
development of neurodegenerative diseases such as
Alzheimer disease (AD) and Parkinson's disease (PD)
[17], in which a local inflammatory response is sustained
by microglial cells, the largest population of phagocytes
associated with the CNS. In normal healthy brain, micro-
glial cells show a typical down-regulated or "resting" phe-
notype when compared to other tissue macrophages, but
they rapidly react in response to a number of acute and
chronic insults. Activated microglial cells could cause neu-
ronal damage via liberation of free radicals as well as
cytokines and toxic factors. Alternatively, microglia can
exert neuroprotective functions by secreting growth fac-
tors or diffusible anti-inflammatory mediators, which
contribute to resolve inflammation and restore tissue
homeostasis [18,19]. Thus, understanding the molecular
mechanisms governing microglial activation is essential
to prevent tissue damage related to excessive activation.
Since nicotine and ACh have been recently reported to
inhibit TNF-α production in mouse microglial cultures,
the aim of our study was to extend our knowledge on the
effect of α7 subunit stimulation on the functional state of
activated microglia. We first confirmed that rat microglia
express the α7 subunit and we demonstrated that, in addi-
tion to inhibit TNF-α, the α7 agonist nicotine significantly
up-regulated COX-2 expression and PGE2 synthesis. Other
important microglial products, such as interleukin-1β (IL-
1β), nitric oxide (NO) and interleukin-10 (IL-10) were
not affected or moderately decreased.
Materials and methods
Reagents
All cell culture reagents were from Gibco (Grand Island,
NY, U.S.A) and virtually endotoxin free (less then 10 E.U./
ml as determined by the manufacturer). BCA protein
assay was from Pierce (Rockford, Illinois). ELISA-kits for
rat TNF-α and IL-10 were from Endogen Inc. (Woburn,
MA). ED-1 monoclonal antibody was from Serotec
(Oxford, UK). (±) Nicotine, α-bungarotoxin, FITC-α-bun-
garotoxin and lipopolysaccharide LPS (from Escherichia
coli, serotype 026:B6) were from Sigma ChemicalJournal of Neuroinflammation 2005, 2:4 http://www.jneuroinflammation.com/content/2/1/4
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(St.Louis, MO). Rabbit polyclonal antibody against alpha
7 subunit was from Santa Cruz Biotechnology.
Cell cultures
Microglial cultures were prepared from 10–14 day mixed
primary glial cultures obtained from the cerebral cortex of
1-day-old rats, as previously described [20] and in accord-
ance with the European Communities Council Directive
N. 86/609/EEC. Microglial cells, harvested from the
mixed primary glial cultures by mild shaking, were resus-
pended in Basal Eagle's Medium (BME) supplemented
with 10 % fetal calf serum, 2 mM glutamine and 100 µg/
ml gentamicin, and plated on uncoated plastic wells at a
density of 1.25 × 105 cells/cm2. Cells were allowed to
adhere for 20 min and then washed to remove non-adher-
ing cells. After a 24 h of incubation, the medium was
replaced with fresh medium containing the substance(s)
under study. Cell viability was greater than 95%, as tested
by Trypan Blue exclusion. Immunostaining, performed as
previously described [20], revealed that cultures consisted
of  ≥ 99% positive cells for the microglia/macrophage
marker ED1. Microglial cells were pre-stimulated for 30
min with nicotine and then stimulated for 24 h in the
presence of 10 ng/ml LPS. A rat pheochromocytoma cell
line, PC12, was propagated and maintained in RPMI-
1640 medium supplemented with 5% heat-inactivated
fetal bovine serum (FBS) and 10% heat-inactivated horse
serum (HS) 100 U/ml penicillin, 100 µg/ml of streptomy-
cin, and 2 mM L-glutamine. The cells were plated in 12-
well plates for 24 h before performing RNA extraction.
Cytokines nitric oxide and PGE2 determination
At the end of the incubation time, cell supernatants were
collected, centrifuged, and stored at -70°C until tested.
The levels of TNF-α and IL-10 were assayed by specific ELI-
SAs, following the manufacturer's instructions. The ranges
of determination were: 31–2500 pg/ml for TNF-α, 10–
1000 pg/ml and 8–500 pg/ml for IL-10. The production of
NO by measuring the content of nitrite, one of the end
products of NO oxidation, as previously described [21].
PGE2 content was quantified using a specific radioimmu-
noassay [21]. The assay detection limit was 25 pg/ml and
cross-reactivity of the antibody for PGE2 with other pros-
taglandins less than 0.25%.
Immunostaining of microglial cells with α-bungarotoxin 
and western blot analysis
Microglial cells were plated on uncoated glass coverslips
(2.5 × 105 cells/cm2), allowed to adhere for 20 min and
then washed to remove non-adhering cells. After a 24 h of
incubation, the complete BME medium was replaced with
fresh BME medium without serum. Cells were incubated
at 4°C for 15 min with FITC-labeled α-bungarotoxin at
1.5 µg/ml. Where indicated, nicotine was added at the
concentration of 500 µM for 10 min, in order to saturate
all the binding sites before the addition of FITC-labeled α-
bungarotoxin. Cells were washed 3 times with BME
medium and then fixed with 4% paraformaldehyde at
room temperature for 15 min. After fixation, coverslips
were washed twice with PBS solution, mounted in
PBS:glycerol and examined using a fluorescent micro-
scope. Cell culture lysates from microglial cells and PC12
cells (used as positive control) were analyzed for α7 sub-
unit expression. Total protein content was estimated using
the Bio-Rad protein assay. An aliquot corresponding to 50
µg (microglia cells) and 20 µg (PC12 cells) of total protein
for each sample was separated by sodium dodecyl sul-
phate polyacrylamide gel elecrophoresis (SDS-PAGE) and
transferred electrophoretically to nylon membranes.
Membranes were blocked with 10% non-fat milk and
incubated with a rabbit policlonal antibodies against α7
subunit (1:2000) overnight at 4°C. Horseradish peroxi-
dase conjugated anti-rabbit IgG (1:5000, 1 h at 25°C) and
ECL reagents were used as detection system.
RNA extraction and semiquantitative RT-PCR analysis
Total RNA was prepared from rat microglia, PC12 cells
and rat hippocampus using Trizol reagent according to
manufacturer's protocol. Two µg of denatured total RNA
were converted into first-strand cDNA using the Super-
Script™synthesis system (Life Technologies™) in a total
reaction volume of 20 µl following the conditions pro-
vided by the manufacturer's protocol.
Oligonucleotide primers with similar Tm were designed
to generate a PCR fragment of 754 bp for the α7 subunit.
PCR conditions (number of cycles and cDNA and primer
concentration) that ensure the data to be obtained within
the exponential phase of amplification of each template
were carefully assessed. The amplification of the β-actin,
COX-2 and α7 subunit within the exponential phase of
amplification was achieved with 25, 30 and 40 cycles
respectively.
Five µl, 15 µl and 40 µl of diluted cDNAs were amplified
for β-actin, COX-2 and α7 respectively. PCR-amplification
was done in a final volume of 50 µl containing 1x PCR
buffer, the four dNTPs (0.2 mM), MgSO4 (2 mM), 1 Unit
of Platinium Taq DNA polymerase High Fidelity (Invitro-
gen). The primers were: α7 subunit (Gene bank accession
number  S53987), sense 5'-TCT GTG CCC TTG ATA
GCAC, antisense 5'-CTT CAT GCA ACC AGG ATC AG,
product length 754; COX-2 [22], sense 5'-TGA TGA CTG
CCC AAC TCC CATG; antisense 5'-AAT GTT GAA GGT
GTC CGG CAGC, product length 702 bp; β-actin (acces-
sion number NM031144) sense 5'-GTC GAC AAC GGC
TCC GGC ATG; antisense 5'-CTC TTG CTC TGG GCC
TCG TCGC, product length 158 bp. A sample containing
all reaction reagents except cDNA was used as PCR nega-
tive control in each experiment. The absence of genomicJournal of Neuroinflammation 2005, 2:4 http://www.jneuroinflammation.com/content/2/1/4
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DNA was verified using 2 µg of RNA from microglia that
was reverse-transcribed without the enzyme (-RT). The
PCR conditions for COX-2 were as follows: initial dena-
turation at 94°C for 2 min followed by 30 cycles of 94°C
for 30 sec, 58°C for 45 sec, 68°C for 1 min, and an addi-
tional cycle with extension at 72°C for 7 min. The PCR
conditions for β-actin were as follows: initial denaturation
at 94°C for 5 min followed by 25 cycles of 94°C for 30
sec, 68°C for 30 sec, 68°C for 45 sec and an additional
cycle with extension at 72°C for 1 min. The PCR condi-
tions for α7 subunit were as follows: initial denaturation
at 94°C for 5 min followed by 40 cycles of 94°C for 30
sec, 57°C for 1 min, 68°C for 45 sec and an additional
cycle with extension at 72°C for 7 min.
PCR products were analyzed by electrophoresis, stained
with ethidium bromide and photographed. Transcript
levels were analyzed by Fluor-STM Multimager analyser
(Biorad). For each experiment, the ratio between optical
density (arbitrary units) of bands corresponding to COX-
2 and β-actin (used as internal standard) was calculated to
quantify the level of the transcripts for COX-2 mRNAs.
Statistical analysis
Data are expressed as mean ± SEM with the number of
independent experiments, run in duplicate, indicated in
figure legends. Comparison between treatment groups
was made by Student's t-test. A two-tailed probability of
less than 5 % (i.e. p < 0.05) was taken as statistically
significant.
Results
Expression of α7 subunit mRNA in microglial cultures
The expression of the mRNA for α7 subunit in rat micro-
glial cells was investigated by RT-PCR. As shown in Figure
1A, we detected a band of the expected size of 754-bp,
which was then confirmed to correspond to α7 subunit by
sequencing (M-Medical, Pomezia, I). The absence of
genomic DNA contamination was demonstrated amplify-
ing 2 µg of total RNA from microglia that was reverse-tran-
scribed without the enzyme (Fig. 1B). As positive controls,
we analyzed the expression of α7 subunit mRNA in rat
hippocampus and PC12 cells (Fig. 1C), known to express
the α7 subunit at high levels [23,24]. The expression of α7
subunit at protein level was established by western blot
analysis using a specific antibody for the α7 subunit,
which recognized a clear band with a molecular mass of
approximately 55 kD from both microglial cells and PC12
cells, used as a positive control (Fig. 2A). The expression
of the receptor was confirmed by labeling microglial cells
with FITC-labeleled-α-bungarotoxin (α-Bgtx), a selective
nicotinic antagonist. Microglial cells were pre-treated for
10 min in the absence (Fig. 2B, left panel) or in the pres-
ence (Fig 2B, right panel) of nicotine (500 µM) before
adding 1.5 µg/ml FITC-α-Bgtx. As shown in Figure 2, a
strong binding of α-Bgtx was observed on the cell surface
of microglial cells (left panel), while nicotine pre-treat-
ment resulted in a marked reduction of the intensity of the
fluorescent signal (right panel).
Effects of nicotine and α7 subunit activation on TNF-α 
release by rat microglial cells
Once we had demonstrated the presence of α7 subunit
mRNA and protein in microglial cells, we studied the
functional consequences of receptor activation using the
specific agonist nicotine. Microglial cells were pre-treated
for 30 min with increasing concentrations of nicotine and
then incubated for 4 or 24 h in the absence or the presence
of 10 ng/ml LPS. In resting microglial cultures nicotine
did not affect the basal level TNF-α(data not shown).
As previously demonstrated using mouse microglial cul-
tures, nicotine pre-treatments dose-dependently inhibited
the release of TNF-α(Fig. 3). At 1 µM concentration, nico-
tine reduced the release of TNF-α after 4 h of LPS stimula-
tion by approximately 35%, an effect similar to that
recently reported for murine microglial cultures [12]. The
inhibitory effect of nicotine on TNF-α release was still sig-
nificant in microglial cultures exposed to LPS for 24 h
(data not shown).
To verify that the effect of nicotine was mediated by α7
subunit, we measured the level of TNF-α in activated
microglial cells exposed to nicotine in the presence or in
the absence of α-Bgtx. The addition of 0.01 µM α-Bgtx
almost totally prevented the inhibitory effect of nicotine
(Fig. 3).
In addition to TNF-α, we also analyzed the release of two
important microglial mediators such as NO and IL-1β and
we found that nicotine pre-treatment only slightly
reduced the release of NO (9 ± 4 and 14 ± 6 % of inhibi-
tion vs LPS activated microglia; n = 9; p < 0.04, for 1 and
10  µM nicotine, respectively) and did not modify the
release of IL-1β (data not shown).
Effects of nicotine and α7 subunit activation on 
interleukin-10 and prostaglandin E2 synthesis by rat 
microglial cells
We then analyzed the effects of nicotine on the produc-
tion of interleukin-10 (IL-10) and prostaglandin E2
(PGE2), two important local mediators with anti-inflam-
matory and immunoregulatory functions. Nicotine pre-
treatment only moderately reduced (18.6 ± 7% of inhibi-
tion vs LPS activated microglia; n = 4; p < 0.03, for 1 µM)
the level of IL-10 in the culture media of microglia cells
stimulated for 24 h with LPS (data not shown).
By contrast, nicotine pre-treatments dose-dependently
enhanced the synthesis of PGE2  in LPS-activatedJournal of Neuroinflammation 2005, 2:4 http://www.jneuroinflammation.com/content/2/1/4
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microglial cells. The presence of 0.01 µM α-Bgtx, blocked
the nicotine-dependent increase of PGE2 released by LPS-
activated microglia (Fig. 4). At this concentration, α-Bgtx
did not by itself affect basal (not shown) or LPS-induced
PGE2. We investigated the molecular mechanism underly-
ing the increased synthesis of PGE2 induced by α7 subunit
stimulation by measuring by RT-PCR the levels of COX-2
mRNA. COX-2 is the enzyme responsible for the first
committed step in prostaglandin synthesis, and is known
to be readily induced by LPS in both peripheral macro-
phages and microglia [25]. As expected, COX-2 mRNA
was expressed at low levels in resting microglial cultures
and was remarkably increased after 7 h and 24 h of LPS
treatment (Fig. 5). The basal COX-2 mRNA level was not
significantly altered by nicotine pre-treatment at any
tested concentration (0.1 µM and 1 µM) or incubation
time (7 and 24 h). However, nicotine pre-treatment
strongly increased the levels of COX-2 mRNA induced by
7 h treatment with 10 ng/ml LPS; the maximal effect was
reached at 0.1 µM concentration (Fig. 5A). The enhancing
effect of nicotine pre-treatment persisted after 24 h of LPS-
treatment, although the increase was significant only at
the lower concentration of nicotine (Fig. 5B).
Discussion
The present study provides evidence that supports the
existence of a cholinergic control of microglial activation.
First, we have confirmed using rat microglial cells previ-
ous data showing that murine microglia express the α7
subunit and that their exposure to the specific agonist nic-
otine reduces LPS-induced release of the pro-inflamma-
tory molecule TNF-α, thus suggesting that these events are
not species specific.
Furthermore, we extended the analysis of α7 subunit acti-
vation to other important microglial functions, including
the synthesis of mediators possessing anti-inflammatory
and immunomodulatory activities. We found that in LPS-
α7 nAChR subunit is expressed in rat microglial cultures Figure 1
α7 nAChR subunit is expressed in rat microglial cultures. Semiquantitative RT-PCR analysis of α7 nAChR mRNA expression in 
rat microglial cells (A) and in PC12 cells and rat hippocampus (C). A 754-bp band corresponding to α7 nAChR was specifically 
amplified (acc. number S53987; amplified region: 906–1660). Expression of β-actin is shown as internal control. No contami-
nation of genomic DNA was present as shown in panel B (-RT: RNA from microglia that was reverse transcribed without the 
enzyme and amplified for α7 subunit).
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activated microglial cells, the interaction of α7 subunit
with its agonist nicotine had moderate or no effect on the
release of NO, IL-1β and IL-10. By contrast, nicotine treat-
ment significantly increased the expression of COX-2 and
the synthesis of PGE2. The effect of nicotine on the LPS-
induced PGE2 release was significantly reversed by the spe-
cific antagonist of α7 subunit, α-bungarotoxin, demon-
strating the involvement of α7 nicotinic receptors in the
induction of PGE2  production by activated microglial
cells.
COX-2 is the inducible isoform of the enzyme responsible
for the first committed step in PGE2 synthesis, one of the
major prostaglandins produced during inflammatory
response and potent modulator of several macrophage
and lymphocyte functions [26]. Within the brain, COX-2
activity and PGE2 production, depending on their levels of
induction, have been associated with both protective and
harmful effects on neurons and glial cells [27]. In micro-
glial cells, COX-2 is the major isoform, rapidly induced by
LPS stimulation or interaction with apoptotic neurons
[28]. The constitutive isoform COX-1 is only moderately
expressed by these cells and is not up-regulated during
their activation [25,27].
PGE2 has been found to be neuroprotective in several
experimental settings. At nanomolar concentrations,
PGE2 protects hippocampal and cortical neuronal cultures
against excitotoxic injury or LPS-induced cytotoxicity [29-
Western blot and fluorescent immunostaining of α7 nAChR in rat microglial cultures Figure 2
Western blot and fluorescent immunostaining of α7 nAChR in rat microglial cultures. A: Proteins from microglial cultures and 
PC12 cells were analysed by western blot (50 ug/lane) using specific polyclonal anti AChRα7 antibodies. B: microglial cells were 
pre-incubated in the absence (B, left panel) or presence of 500 µM nicotine (B, right panel) for 10 min and then incubated with 
FITC-labeleled-α-Bgtx (1.5 µg/ml) for 15 min at 4°C. A strong binding of α-Bgtx was observed on the cell surface of microglial 
cells. Nicotine pre-treatment resulted in a marked reduction of the intensity of binding.
Effects of specific α7 nAChR agonist and antagonist on TNF- α production by activated rat microglial cultures Figure 3
Effects of specific α7 nAChR agonist and antagonist on TNF-
α production by activated rat microglial cultures. Microglial 
cells were subcultured for 24 h in 10% FCS-containing 
medium, which was replaced with fresh medium before stim-
ulation. Nicotine (0.1–1 µM) and/or α-Bgtx were added 30 
min before LPS stimulation (10 ng/ml). Supernatants were 
collected after 4 h and analyzed for TNF-α content. Data are 
shown as mean ± SEM for 3 independent experiments, run in 
duplicate. *p < 0.03 vs LPS.
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32]. In hippocampal neuronal and organotypic cultures,
the protective effect of PGE2 against glutamate and oxygen
deprivation is mediated by the activation of the EP2 recep-
tor, one of the four PGE2 receptor subtypes whose activa-
tion leads to cAMP formation [31]. The protective effect of
EP2 receptor activity has been confirmed in vivo, in a
model of transient forebrain ischemia, in which the
genetic deletion of this PGE2  receptor exacerbates the
extent of neuronal damage [31]. On the other hand, at
concentrations in the µM – mM range, PGE2 contributes
to neuronal death and stimulates release of glutamate by
astrocytes [33-35].
PGE2 has also been shown to down-regulate microglial
activation and expression of pro-inflammatory genes,
including TNF-α, both in vitro and in vivo [36,37]. We
have recently found that the interaction of microglial cells
with apoptotic neurons promotes the synthesis of PGE2
along with neuroprotective and immunoregulatory mole-
cules such as TGF-β and NGF [38,28]. In this system, the
release of PGE2 is triggered by the specific interaction
between phosphatidylserine, a phospholipid exposed on
the cell surface during the initial phase of apoptosis, with
its cognate receptor expressed by microglia [39], consist-
ent with previous studies on peripheral macrophages
[40]. It has been suggested that the PGE2, released by mac-
rophages engulfing apoptotic cells, contributes to one of
the main features of apoptotic cell death, namely the effi-
cient removal of dying cells without eliciting inflamma-
tion in the surrounding tissue [41]. It is therefore
tempting to speculate that the α7 subunit-dependent
increase of PGE2 in activated microglia cells is part of an
anti-inflammatory pathway regulated by the cholinergic
system. The detection of microglial cells, astrocyte proc-
esses and choline acetyltransferase- (ChAT-) positive fib-
ers around β-amyloid plaques in transgenic APPSW mice
suggests a close connection between cholinergic terminals
and microglial cells [42]. A deficit in ACh level due to loss
of cholinergic neurons associated with AD as well as aging
could contribute to the establishment of chronic inflam-
mation rendering microglial cells more susceptible
towards environmental changes and orientating them
towards a pro-inflammatory phenotype. However, to date
there is no definitive evidence of a causal link between
loss of cholinergic neurons and increased levels of pro-
inflammatory cytokines such as TNF.
In the last few years, several lines of evidence have sug-
gested that activation of α7 subunits plays an important
role in the maintenance of cognitive functions in several
neurodegenerative disorders [43]. Epidemiological stud-
ies have shown that cigarette smoking can be protective
against the development of AD, PD and other types of
dementia, suggesting that chronic inhalation of nicotine
may slow the progression of these neurodegenerative dis-
eases or improve some cognitive responses in AD patients
[44,17]. Loss of nAChRs has been reported in patients
with diverse forms of dementia [45]. In particular, a
reduction in α7 subunit number was detected in AD and
PD brain tissue specimens [46]. The administration of lig-
ands targeting nicotinic receptors in animal models of
neurodegeneration, as well as in humans, induced cogni-
tive improvement [47] and conferred neuroprotection
against several neurotoxic agents [48,49]. Furthermore,
cholinesterase inhibitors used in the symptomatic treat-
ment of AD have been reported to exert additional bene-
fits through the increased density of specific nicotinic
receptor subunits (including the α7) [50]. This effect
could be relevant in view of the anti-inflammatory role
suggested for the α7 subunit.
As mentioned in the introduction, the presence of α7 sub-
unit on immune cells as well as on other non-excitable
cells has provided a molecular basis for a non-neuronal
cholinergic pathway that might function as an essential
regulator of inflammation as well as immune responses
Effect of specific α7 nAChR agonist and antagonist on PGE2  synthesis by activated rat microglial cultures Figure 4
Effect of specific α7 nAChR agonist and antagonist on PGE2 
synthesis by activated rat microglial cultures. Microglial cells 
were subcultured as in Fig. 3, and nicotine (0.1–1 µM) added 
30 min before LPS stimulation (10 ng/ml). Supernatants were 
collected after 24 h and analyzed for PGE2 content. Data, 
with induction expressed as a percentage of LPS-induced 
PGE2 production, are shown as mean ± SEM for 5 independ-
ent experiments, run in duplicate. The levels of PGE2 were 
undetectable in basal conditions, and were 24 ± 6 ng/mg pro-
tein after LPS-stimulation for 24 h. *p < 0.05 vs LPS; **p < 
0.02 vs LPS.
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[4,5]. Primary cultures of astrocytes and microglia show
ChAT activity and synthesize acetylcholine [51]. Accord-
ingly, we have found the expression of ChAT mRNA in
both resting and activated microglia cells (unpublished
results). This suggests that this neurotransmitter may act
as a local hormone and contribute to the regulation of
microglial functions.
It should be noted that although our study focused on the
effects of nicotine on the process of microglial activation
induced by LPS, our findings may have broader implica-
tions since other microglial activators, such as pro-inflam-
matory cytokines and fibrillogenic peptides, share some
common signaling pathways with LPS [52,53]. In addi-
tion, it has been recently reported that the LPS receptor
CD14 interacts with fibrils of Alzheimer amyloid peptide
and a deficiency of this receptor significantly reduces
fibril-induced microglial activation [54].
At present, the signaling pathways downstream to α7 sub-
unit activation and leading, in particular, to COX-2 and
PGE2 up-regulation is under investigation. Shytle et al.
Semiquantitative RT-PCR analysis of COX-2 mRNA Figure 5
Semiquantitative RT-PCR analysis of COX-2 mRNA. Representative semi-quantitative RT-PCR analysis of COX-2 mRNA in 
microglial cultures, subcultured as in Fig. 3, pre-treated with nicotine (Nic, 0.1–1 µM) for 30 min and stimulated for 7 h (A, 
upper panels) or 24 h (B upper panels) with LPS (10 ng/ml). The amount of COX-2 mRNA, expressed as the ratio of densito-
metric measurement of the sample to the corresponding internal standard (β-actin), is shown in the lower panels. Data are 
shown as mean ± SEM for 3 to 4 independent experiments, with the exception of 1 µM nicotine, panel A (n = 2); all run in 
duplicate. * p < 0.05 vs fcs; **p < 0.05 vs fcs.
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[12] have reported that either ACh or nicotine inhibit LPS-
induced phosphorylation of the mitogen-activated pro-
tein kinases p44/42 and p38 in murine microglia. We
have recently found a reduction of p38 phosphorylation
in two experimental settings in which exposure of micro-
glial cells to phosphatidylserine vesicles – mimicking apo-
pototic neurons – or to chronic activation stimuli,
resulted in downregulation of pro-inflammatory
cytokines and in enhancement of PGE2 synthetic pathway
[55,56], thus suggesting that p38 may also have a role in
α7 dependent up-regulation of COX-2.
Conclusions
Activation of α7 nicotinic receptors in microglial cells by
nicotine controls some important microglial functions,
thus preventing chronic inflammation. Since microglial
activation and chronic inflammation have been associ-
ated with most neurodegenerative pathologies [57] the
understanding of the molecular pathway(s) triggered by
α7 subunit activation in microglial cells will offer new
venues for potential pharmacological regulation of micro-
glial activation in neurodegenerative diseases. At the same
time, the development of molecules able to stimulate the
α7 subunit may represent a potential promising approach
for the treatment of these disorders.
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